Pre-operative risk assessment and risk reduction before surgery

Area of Science:

• Cardiology
• Perioperative Medicine
• Cardiac Surgery

Background:

• Perioperative myocardial infarction (MI) is a leading cause of death and disability in patients undergoing noncardiac surgery.
• The complex pathophysiology involves prolonged ischemia from surgical stress and coronary lesions, alongside plaque rupture and thrombus formation.
• Traditional management focused on addressing the culprit coronary lesion.

Purpose of the Study:

• To review the evolving strategies in perioperative myocardial infarction management.
• To highlight the shift towards systemic medical therapy for prevention and plaque stabilization.
• To guide perioperative cardiac testing and risk factor modification.

Main Methods:

• Review of current literature and clinical practice guidelines.
• Analysis of the pathophysiology of perioperative myocardial infarction.
• Evaluation of the role of medical therapies (beta-blockers, statins, aspirin) and revascularization.

Main Results:

• A paradigm shift has occurred from invasive lesion treatment to systemic medical therapy.
• Beta-blockers, statins, and aspirin are key components of current perioperative cardiac care.
• Prophylactic coronary revascularization is reserved for standard indications, not solely for perioperative risk reduction.
• Pre-operative cardiac testing is recommended only when results influence perioperative management.

Conclusions:

• Current perioperative management emphasizes systemic medical therapy to prevent myocardial oxygen supply-demand imbalance and stabilize coronary plaques.
• Physicians should leverage the perioperative period for lifestyle changes and medical therapy to mitigate cardiac risk factors.
• Optimizing patient condition through risk factor modification improves long-term outcomes and surgical benefits.